TC BioPharm Ltd (TCBP) ADR Each Representing 20 Ord Share SPON
$0.04
(4.65%)
- Add to watchlist
- This stock can be held in a
$0.04
(4.65%)
$0.04
(4.65%)
Business summary
TC BioPharm Limited is a clinical-stage cell therapy company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. Its platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. Its pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications. The Company’s therapies are focused on leveraging the inherent biological capabilities of GDT cells together with an integrated cell engineering approach.
Contact details
Important dates
General stock information
- Short code:
- TCBP
- ISIN:
- US87807D4007
- Market cap:
- $4.22 million
- Shares in issue:
- 63.90 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.